Letter to the Editor| Volume 96, P128-130, June 2018

Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure

Published:April 18, 2018DOI:
      A 51-year-old man was diagnosed with muscle-invasive urothelial bladder carcinoma with a transurethral resection of the bladder (TURB) in February 2016. The radiological staging with whole-body computed tomography (CT) scan and 18-fluorine fluorodeoxyglucose positron emission tomography (PET/CT) scan revealed multiple bone and lymph node metastases (enlarged mediastinal, retroperitoneal and pelvic lymph nodes).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Frampton G.M.
        • Fichtenholtz A.
        • Otto G.A.
        • et al.
        Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
        Nat Biotechnol. 2013; 31: 1023-1031
        • Wagle N.
        • Grabiner B.C.
        • Van Allen E.M.
        • et al.
        Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
        Cancer Discov. 2014; 4: 546-553
        • Iyer G.
        • Al-Ahmadie H.
        • Schultz N.
        • et al.
        Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.
        J Clin Oncol. 2013; 31: 3133-3140
        • Robertson A.G.
        • Kim J.
        • Al-Ahmadie H.
        • et al.
        Comprehensive molecular characterization of muscle-invasive bladder cancer.
        Cell. 2017; 171 (540–556.e25)
        • Bryant H.E.
        • Schultz N.
        • Thomas H.D.
        • et al.
        Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
        Nature. 2005; 434: 913-917
        • Farmer H.
        • McCabe N.
        • Lord C.J.
        • et al.
        Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
        Nature. 2005; 434: 917-921
        • Helleday T.
        The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
        Mol Oncol. 2011; 5: 387-393
        • Lord C.J.
        • Ashworth A.
        BRCAness revisited.
        Nat Rev Cancer. 2016; 16: 110-112
        • Mateo J.
        • Carreira S.
        • Sandhu S.
        • et al.
        DNA-repair defects in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Teo M.Y.
        • Seier K.
        • Ostrovnaya I.
        • et al.
        DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).
        J Clin Oncol. May 2017; 35 (4509–4509)
        • Apolo A.B.
        • Parnes H.L.
        • Francis D.C.
        • et al.
        A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).
        J Clin Oncol. 2016; 34 (suppl; abstr 4534)
        • Sweis R.F.
        • Spranger S.
        • Bao R.
        • et al.
        Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer.
        Cancer Immunol Res. 2016; 4: 563-568